A subscription to JoVE is required to view this content. Sign in or start your free trial.
* These authors contributed equally
Based on the familial hereditary cardiomyopathy family found in our clinical work, we created a C57BL/6N mouse model with a point mutation (G823E) at the mouse MYH7 locus through CRISPR/Cas9-mediated genome engineering to verify this mutation.
Familial hypertrophic cardiomyopathy (HCM, OMIM: 613690) is the most common cardiomyopathy in China. However, the underlying genetic etiology of HCM remains elusive.
We previously identified a myosin heavy chain 7 (MYH7) gene heterozygous variant, NM_000257.4: c.G2468A (p.G823E), in a large Chinese Han family with HCM. In this family, variant G823E cosegregates with an autosomal dominant disorder. This variant is located in the lever arm domain of the neck region of the MYH7 protein and is highly conserved among homologous myosins and species. To verify the pathogenicity of the G823E variant, we produced a C57BL/6N mouse model with a point mutation (G823E) at the mouse MYH7 locus with CRISPR/Cas9-mediated genome engineering. We designed gRNA targeting vectors and donor oligonucleotides (with targeting sequences flanked by 134 bp of homology). The p.G823E (GGG to GAG) site in the donor oligonucleotide was introduced into exon 23 of MYH7 by homology-directed repair. A silenced p.R819 (AGG to CGA) was also inserted to prevent gRNA binding and re-cleavage of the sequence after homology-directed repair. Echocardiography revealed left ventricular posterior wall (LVPW) hypertrophy with systole in MYH7 G823E/- mice at 2 months of age. These results were likewise validated by histological analysis (Figure 3).
These results demonstrate that the G823E variant plays an important role in the pathogenesis of HCM. Our findings enrich the spectrum of MYH7 variants linked to familial HCM and may provide guidance for genetic counseling and prenatal diagnosis in this Chinese family.
Hypertrophic cardiomyopathy (HCM, OMIM: 613690) is the most common cardiomyopathy in China, with an estimated incidence of 0.2%, affecting 150,000 people1,2.
The pathological anatomical feature that characterizes HCM is asymmetric ventricular hypertrophy, which often involves the ventricular outflow tract and/or interventricular septum3. The clinical manifestation is exertional dyspnea, fatigue, and chest pain. The individual phenotype of HCM has variability ranging from clinically insidious to severe heart failure. Patients with HCM require medical treatment....
The histories of the families were obtained by interviewing the family members. The study was approved by the Ethics Committee of the Guangdong Provincial Hospital of Chinese Medicine (No. 2019074). Informed written consent was obtained from all the family members. All the animals are treated in accordance with the ethical guidelines of the Guangdong Provincial Hospital of Chinese Medicine (Guangzhou, China).
1. Study subjects
NOTE: The proband III-3 .......
Clinical profile of the families
The family pedigrees of HCM were obtained and are shown in Figure 2. All the documented family members were diagnosed with HCM at enrollment.
In the family (Figure 2A), the proband was patient III-7, who was diagnosed with HCM and left ventricular outflow tract obstruction (LVOTO) at 46 years old and underwent cardiac surgery. Patient III-3 had minor HCM that did not require surgical treatment. P.......
In this study, we describe one Chinese Han families with HCM. Genetics analysis revealed that a heterozygous MYH6 mutation p.G823E co-segregates with the disease in family members with autosomal dominant inheritance. To validate the pathogenicity of G823E mutation and discuss the underlying mechanisms, we created a C57BL/6N mouse model with G823E at mouse Myh7 locus by CRISPR/Cas9-mediated genome engineering.
Phenotypic characteristics of C57BL/6N-Myh7em1(G823E) knockin mice were ev.......
This work was supported by the Medical Research Fund project of Guangdong Province (A2022363) and the major project of the Guangdong Committee of Science and Technology, China (grant no.2022).
We would like to thank Qingjian Chen of the University of Maryland, College Park for the help during the preparation of this manuscript.
....Name | Company | Catalog Number | Comments |
0.5×TBE | Shanghai Sangon | ||
2× Taq Master Mix (Dye Plus) | Nanjing Novizan Biotechnology Co., Ltd. | ||
Agarose | Regu | ||
Anesthesia machine for small animals | Reward Life Technology Co., Ltd. | R500 | |
BEDTools | 2.16.1 | ||
Cas9 in vitro digestion method to detect gRNA target efficiency kit | Viewsolid Biotechnology Co., Ltd. | VK007 | |
DNA Marker | Thermo Fisher Scientific | ||
DNA stabilizer | Shanghai Seebio Biotechnology Co., Ltd. | DNAstable LD | prevent DNA degradation |
Electric paraffin microtome | Shenyang Hengsong Technology Co., Ltd. | HS-S7220-B | |
GATK | v3.5 | ||
Gentra Puregene blood kit | Santa Clara | ||
Glass slide, coverslip | Jiangsu Invotech Biotechnology Co., Ltd. | ||
Hematoxylin staining solution, Eosin staining solution | Shanghai Biyuntian Biotechnology Co., Ltd. | C0107-500ml, C0109 | |
HiSeq X-ten platform | Illumina | perform sequencing on the captured libraries | |
Injection of chorionic gonadotropin | Livzon Pharmaceutical Group Inc. | ||
Injection of pregnant mare serum gonadotropin | Livzon Pharmaceutical Group Inc. | ||
Isoflurane | Local suppliers | inhalation anesthesia | |
Microinjection microscope | Nikon | ECLIPSE Ts2 | |
NanoDrop | Thermo Fisher Scientific | 2000 | |
Paraffin Embedding Machine | Shenyang Hengsong Technology Co., Ltd. | HS-B7126-B | |
Picard | (2.2.4) 20 | ||
Proteinase K | Merck KGaA | ||
samtools | 1.3 | ||
Sequencer | Applied Biosystems | ABI 3500 | |
Stereomicroscope | Nikon | SMZ745T | |
SureSelect Human All Exon V6 | Agilent Technology Co., Ltd. | exome probe | |
T7 ARCA mRNA Kit | New England BioLabs, Inc. | NEB-E2065S | |
Temperature box | BINDER GmbH | KBF-S Solid.Line | |
Trizma Hydrochloride Solution | Sigma, Merck KGaA | No. T2663 | |
Veterinary ultrasound system | Royal Philips | CX50 |
This article has been published
Video Coming Soon
ABOUT JoVE
Copyright © 2024 MyJoVE Corporation. All rights reserved